Application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma

An anti-liver cancer, multi-purpose technology, applied in the field of biotechnology and medicine, can solve the problems of undeveloped liver cancer treatment drugs

Inactive Publication Date: 2013-06-05
SHANGHAIMED
View PDF4 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although studies have confirmed that the abnormal activation of the IL-6/IL-6R/gp130 signaling pathway plays a key role in the development of various tumors (for example, IL-6/IL-6R/gp130 signaling as a therapeutic t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma
  • Application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma
  • Application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Example 1: Inhibitory Effect of Antagonizing and / or Blocking IL-6 / IL-6R / gp130 Signaling Pathway on Proliferation of Liver Cancer Cells Cultured in Vitro

[0090] Experimental Materials

[0091] Liver cancer cell line Huh7 cells (purchased from Shanghai Cell Bank, Chinese Academy of Sciences);

[0092] Human IgG (purchased from R&D Company) was used as the experimental control (concentration used was the same as that of the corresponding experimental group antibody concentration);

[0093] Anti-IL-6 neutralizing monoclonal antibody Siltuximab (used at a concentration of 5 μg / ml) (purchased from R&D Company);

[0094] Anti-IL-6R blocking monoclonal antibody Tocilizumab (used at a concentration of 5 μg / ml) (purchased from R&D Company);

[0095] Anti-gp130 blocking monoclonal antibody RX435 (used at a concentration of 5 μg / ml) (purchased from R&D Company);

[0096] Experimental control uses DMSO (concentration consistent with that of (+)-Madindoline A) (purchased from Si...

Embodiment 2

[0108] Example 2: Promoting effect of antagonizing and / or blocking IL-6 / IL-6R / gp130 signaling pathway on apoptosis of liver cancer cells cultured in vitro

[0109] Experimental Materials (material source is with embodiment 1)

[0110] Liver cancer cell line Huh7 cells;

[0111] Human IgG was used as the experimental control (the concentration used was consistent with the antibody concentration of the corresponding experimental group);

[0112] Anti-IL-6 neutralizing monoclonal antibody Siltuximab (used at a concentration of 5 μg / ml);

[0113] Anti-IL-6R blocking monoclonal antibody Tocilizumab (used at a concentration of 5 μg / ml);

[0114] Anti-gp130 blocking monoclonal antibody RX435 (used at a concentration of 5 μg / ml);

[0115] DMSO was used as the experimental control (the concentration used was consistent with that of (+)-Madindoline A);

[0116] gp130-specific inhibitor (+)-Madindoline A (used at a concentration of 10 μg / ml).

[0117] experimental method

[011...

Embodiment 3

[0125] Example 3: Inhibitory effect of antagonizing and / or blocking IL-6 / IL-6R / gp130 signaling pathway on tumorigenesis of subcutaneous liver cancer cells in nude mice

[0126] Experimental Materials (except mice, material sources are the same as in Example 1)

[0127] Liver cancer cell line Huh7 cells;

[0128] Human IgG was used as the experimental control (the concentration used was consistent with the antibody concentration of the corresponding experimental group);

[0129] Anti-IL-6 neutralizing monoclonal antibody Siltuximab (used at a concentration of 10 mg / kg body weight per day);

[0130] Anti-IL-6R blocking monoclonal antibody Tocilizumab (used at a concentration of 10 mg / kg body weight per day);

[0131] Anti-gp130 blocking monoclonal antibody RX435 (used at a concentration of 10 mg / kg body weight per day);

[0132] DMSO was used as the experimental control (the concentration used was consistent with that of (+)-Madindoline A);

[0133] gp130-specific inhibito...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma, and specifically relates to an application of an antagonist and/or a blocking agent of the IL-6/IL-6R/gp130 signaling pathway and conventional liver cancer treatment drugs (such as cisplatin, doxorubicin and sorafenib) in preparation of anti-hepatoma drug compositions. The composition provided by the invention has significant curative effect for the liver cancers and has the advantages of small toxic and side effects, capability for synergizing with the conventional liver cancer treatment drugs and increasing the effect of the conventional anti-hepatoma treatment, and the like.

Description

technical field [0001] The invention belongs to the fields of biotechnology and medicine. Specifically, the present invention relates to a new method for treating liver cancer, which is to antagonize and / or block IL-6 / IL-6R / gp130 signaling pathway; meanwhile, it is proved that the method has a synergistic effect when used in combination with existing drugs for treating liver cancer. Therefore, the present invention provides an IL-6 / IL-6R / gp130 signaling pathway antagonist and / or blocker or its combination with existing liver cancer treatment drugs in the treatment of liver cancer. Background technique [0002] Primary liver cancer is one of the most important health threats worldwide. It is the fifth most common tumor and the third leading cause of cancer-related death in the world. It increases by more than 560,000 new cases of liver cancer each year and causes more than 500,000 patient died. Among them, hepatocellular carcinoma originates from liver cells, accounting for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K45/06A61K39/395A61P35/00
Inventor 顾建新徐洁杰恽小婧刘海鸥周蕾
Owner SHANGHAIMED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap